{
  "docId": "019de071-7055-71be-8e36-ff3241c1e380",
  "docSlug": "06f5a1d0d7573c1d13069d999ff5f2e2",
  "documentTitle": "RenovoRx | IPO Presentation Deck | 29 slides",
  "authorId": "renovorx",
  "authorName": "RenovoRx",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investment_bank",
  "sourceTypeLabel": "Investment bank",
  "presentationDate": "2021-08-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7843866,
  "pageNumber": 6,
  "pageCount": 29,
  "prevPage": 5,
  "nextPage": 7,
  "slideType": "problem_statement",
  "function": "frame_problem",
  "density": "dense",
  "nDataPoints": 6,
  "notes": null,
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de071-7055-71be-8e36-ff3241c1e380/6",
  "deckHref": "/decks/019de071-7055-71be-8e36-ff3241c1e380",
  "deckJsonHref": "/decks/019de071-7055-71be-8e36-ff3241c1e380.json",
  "deckAnchorHref": "/decks/019de071-7055-71be-8e36-ff3241c1e380#slide-6",
  "components": [
    {
      "bbox": {
        "h": 0.04,
        "w": 0.12,
        "x": 0.85,
        "y": 0.04
      },
      "kind": "image",
      "text": "RenovoRx",
      "attrs": null,
      "subkind": "logo",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e531dacd-c91b-49bd-9ae2-288263ffb845",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.65,
        "w": 0.45,
        "x": 0.51,
        "y": 0.25
      },
      "kind": "list",
      "text": "Hilar Cholangiocarcinoma (HCCA): Poor prognosis, 2nd most common primary liver tumor (7k cases/yr). Current SOC: No established standard due to toxicity; Gemcitabine/cisplatin used in ABC-2 trial.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a31260bb-c252-44b0-9bbd-142f0dbf378c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.65,
        "w": 0.45,
        "x": 0.04,
        "y": 0.25
      },
      "kind": "list",
      "text": "Pancreatic Cancer: One of the deadliest cancers, 5-10% 5-year survival, 60k diagnosed/48k deaths in 2021, 30% are LAPC. Current SOC: Gemcitabine/Abraxane (2013), 12-15 month median survival.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "bf7a656e-970d-4727-9906-274454e71720",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.75,
        "x": 0.04,
        "y": 0.04
      },
      "kind": "title",
      "text": "First and Second Indications: Locally Advanced Pancreatic Cancer and Hilar Cholangiocarcinoma",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8018c5f9-cd39-4c4a-8cb6-d9bb01f1ec32",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Audience Definition",
      "slug": "audience-definition",
      "agent": "Storyteller",
      "layer": "slide",
      "matchId": "bd16a157-0782-44a2-827c-041f90883f77",
      "evidence": "medical terms and statistics are presented",
      "confidence": 0.5
    },
    {
      "name": "Problem Statement Canvas",
      "slug": "problem-statement-canvas",
      "agent": "Architect",
      "layer": "slide",
      "matchId": "ba279515-ce2f-499e-961e-8f0ca15dc337",
      "evidence": "list/bullet components describe a problem",
      "confidence": 0.7
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 7,
      "from": 6,
      "beatId": "4f935263-c01b-453a-ad37-3d2082674c51",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Problem",
      "beatSlug": "sequoia-pitch-problem",
      "evidence": "Slides 6-7 present the problem statement",
      "position": 0,
      "confidence": 0.8,
      "parentBeatName": "Complication",
      "parentBeatSlug": "complication"
    }
  ],
  "loops": [
    {
      "to": 7,
      "from": 6,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "b857b3dc-50ec-486b-a68a-132de938f76a",
      "evidence": "Slides 6-7 present the problem statement",
      "position": 0,
      "objective": "Highlight the limitations of current chemotherapy regimens",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.7,
      "description": "Quantify what happens if the audience does nothing"
    },
    {
      "to": 28,
      "from": 4,
      "name": "Golden Circle",
      "slug": "11-golden-circle",
      "bestFor": "Visionary leadership, brand positioning, mission statements",
      "matchId": "eeb5d12f-412a-4325-8fbd-2a39f305b6d7",
      "evidence": "Slides 4 and 28 present the executive summary and investment highlights",
      "position": 1,
      "objective": "Present the investment highlights and ask",
      "structure": "The Why (Belief) -> The How (Process) -> The What (Result)",
      "confidence": 0.6,
      "description": "Invert the typical pitch by starting with why you exist, rather than what you do"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}